<DOC>
	<DOCNO>NCT03062319</DOCNO>
	<brief_summary>The Purpose open-label randomize controlled multicenter trial evaluate efficacy safety mono-drug therapy oral anticoagulant compare combination therapy antiplatelet drug , ischemic stroke patient non-valvular atrial fibrillation atherothrombosis .</brief_summary>
	<brief_title>Optimal Antithrombotic Therapy Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation Atherothrombosis</brief_title>
	<detailed_description>The Purpose open-label randomize controlled multicenter trial evaluate efficacy safety mono-drug therapy oral anticoagulant compare combination therapy antiplatelet drug , ischemic stroke patient non-valvular atrial fibrillation atherothrombosis . Target sample size 400 . The primary outcome composite endpoint ischemic cardiovascular event ( cardiovascular death , ischemic stroke , myocardial infarction , systemic embolism , ischemic event require urgent revascularization ) major bleeding define International Society Thrombosis Haemostasis ( ISTH ) criterion within 2 year randomization .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>1 . Patients acute ischemic stroke TIA 15 day 180 day onset symptom 2 . Age : 2090 year . 3 . Patients nonvalvular atrial fibrillation ( chronic paroxysmal ) start continue take oral anticoagulant 4 . Patients one follow atherothrombotic disease 1 . A past history ischemic heart disease ( myocardial infarction , angina pectoris , coronary artery bypass graft ( CABG ) , percutaneous coronary intervention ( PCI ) 2 . A past history peripheral artery disease ( symptomatic peripheral arterial occlusive disease , low extremity bypass surgery/angioplasty/stenting ) 3 . Carotid artery stenosis ( symptomatic asymptomatic ( = &gt; 50 % diameter ) , history carotid artery stenting ( CAS ) carotid endarterectomy ( CEA ) ) 4 . Intracranial artery stenosis ( = &gt; 50 % stenosis diameter major intracranial artery : intracranial internal carotid artery , anterior cerebral artery ( ACA ) A1 A2 , middle cerebral artery ( MCA ) M1 M2 , posterior cerebral artery ( PCA ) P1 P2 , vertebral artery , basilar artery ; history intracranial stent placement intracranial bypass surgery ) 5 . A past history atherothrombotic brain infarction , lacunar infarction , branch atheromatous disease 5 . Patients walk independently ( modify Rankin Scale score = &lt; 3 ) 6 . Patients take oral medication 7 . Patients receive followup survey 8 . Provision write informed consent either directly suitable surrogate 1 . History myocardial infarction acute coronary syndrome within past 12 month 2 . Patients underwent PCI drugeluting stent within past 12 month PCI baremetal stent within past 3 month 3 . Patients underwent carotid artery stent placement , intracranial stent placement , low extremity stent placement within past 3 month 4 . History symptomatic intracranial hemorrhage gastrointestinal bleeding within past 6 month 5 . Hemorrhagic diathesis blood coagulation disorder 6 . Platelet count &lt; 100,000 /mm3 enrollment . 7 . Severe anemia ( hemoglobin &lt; 7 g/dL ) 8 . Severe renal failure ( creatinine clearance = &lt; 15 mL/min ) undergo chronic hemodialysis . 9 . Severe liver dysfunction ( Grade B C ChildPugh classification ) 10 . Patients unable walk independently ( modify Rankin Scale score = &gt; 4 ) 11 . Pregnant possibly pregnant woman 12 . Active cancer 13 . Expectation survival le 2 year 14 . Anticoagulant antiplatelet schedule discontinue 4 week followup period 15 . Planned revascularization procedure followup period 16 . Patients enrol trial 17 . Patients judge inappropriate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>antiplatelet</keyword>
</DOC>